Advances in Treatment of Cholestatic Liver Diseases / 胃肠病学
Chinese Journal of Gastroenterology
; (12): 238-241, 2020.
Article
en Zh
| WPRIM
| ID: wpr-861693
Biblioteca responsable:
WPRO
ABSTRACT
Cholestatic liver diseases (CLD) are a series of hepatobiliary diseases characterized by dysfunction of bile formation, secretion and excretion and are induced by immune, genetic and environmental factors. The development and pathogenesis of CLD is still unclear, and it has a risk of progression to liver fibrosis and cirrhosis. Traditional medicines such as ursodeoxycholic acid (UDCA), glucocorticoids and immunosuppressants have certain limitations. More and more studies provide new insights into the mechanism of cholestasis to explore the therapeutic targets, and various drugs such as all-trans retinoic acid, microecologics and norursodeoxycholic acid emerge as new therapeutic drugs. This article reviewed the advances in treatment of CLD.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Gastroenterology
Año:
2020
Tipo del documento:
Article